Literature DB >> 16629385

Therapeutic potential of RNAi in metabolic diseases.

Cristina M Rondinone1.   

Abstract

Over the past years RNA interference (RNAi) has exploded as a new approach to manipulate gene expression in mammalian systems. More recently, RNAi has acquired interest as a potential therapeutic strategy. This review focuses on the potential therapeutic use of RNAi for metabolic diseases, the current understanding of RNAi biology, and how RNAi has been utilized to study the role of different genes in the pathogenesis of diabetes and obesity. Also reviewed are the in vivo proof-of-principle experiments that provide the preclinical justification for the development of RNAi-based therapeutics for diabetes and the key challenges that currently limit its application in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16629385     DOI: 10.2144/000112163

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  6 in total

1.  Non-small cell lung carcinoma therapy using mTOR-siRNA.

Authors:  Hirochika Matsubara; Kenji Sakakibara; Tamo Kunimitsu; Hiroyasu Matsuoka; Kaori Kato; Noboru Oyachi; Yoh Dobashi; Masahiko Matsumoto
Journal:  Int J Clin Exp Pathol       Date:  2012-02-12

2.  Novel liver-specific TORC2 siRNA corrects hyperglycemia in rodent models of type 2 diabetes.

Authors:  Maziyar Saberi; David Bjelica; Simon Schenk; Takeshi Imamura; Gautam Bandyopadhyay; Pingping Li; Vasant Jadhar; Chandra Vargeese; Weimin Wang; Keith Bowman; Ye Zhang; Barry Polisky; Jerrold M Olefsky
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-08-25       Impact factor: 4.310

Review 3.  Specificity of insulin signalling in human skeletal muscle as revealed by small interfering RNA.

Authors:  A Krook; J R Zierath
Journal:  Diabetologia       Date:  2009-03-31       Impact factor: 10.122

Review 4.  An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment.

Authors:  Jacob Lorenzo-Morales; Naveed A Khan; Julia Walochnik
Journal:  Parasite       Date:  2015-02-18       Impact factor: 3.000

Review 5.  Non-viral siRNA delivery to the lung.

Authors:  Mini Thomas; James J Lu; Jianzhu Chen; Alexander M Klibanov
Journal:  Adv Drug Deliv Rev       Date:  2007-03-15       Impact factor: 15.470

6.  Introducing an In Vitro Liver Stability Assay Capable of Predicting the In Vivo Pharmacodynamic Efficacy of siRNAs for IVIVC.

Authors:  Babak Basiri; Fang Xie; Bin Wu; Sara C Humphreys; Julie M Lade; Mai B Thayer; Pam Yamaguchi; Monica Florio; Brooke M Rock
Journal:  Mol Ther Nucleic Acids       Date:  2020-07-10       Impact factor: 8.886

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.